Presentation is loading. Please wait.

Presentation is loading. Please wait.

Subgroup analyses of association of gout with incident AF by clinical characteristics that are risk factors for AF. Point estimates indicate the HR of.

Published byCaitlin McGee Modified over 6 years ago

Similar presentations

Presentation on theme: "Subgroup analyses of association of gout with incident AF by clinical characteristics that are risk factors for AF. Point estimates indicate the HR of."— Presentation transcript:

1 Subgroup analyses of association of gout with incident AF by clinical characteristics that are risk factors for AF. Point estimates indicate the HR of incident AF with gout and the whiskers 95% CI. We show these for each subgroup analysis, based on the presence or absence of each disease. Subgroup analyses of association of gout with incident AF by clinical characteristics that are risk factors for AF. Point estimates indicate the HR of incident AF with gout and the whiskers 95% CI. We show these for each subgroup analysis, based on the presence or absence of each disease. The horizontal line through HR of 1 represents null hypothesis. Any HR with 95% CI that overlaps this line is not statistically significant. AF, atrial fibrillation. Jasvinder A Singh, and John D Cleveland RMD Open 2018;4:e000712 Copyright © BMJ Publishing Group & EULAR. All rights reserved.

Download ppt "Subgroup analyses of association of gout with incident AF by clinical characteristics that are risk factors for AF. Point estimates indicate the HR of."

Similar presentations

Copyright © 2016 American Medical Association. All rights reserved.

Copyright © 2016 American Medical Association. All rights reserved.
Multivariable model of abatacept retention in biologic-naïve patients.

Multivariable model of abatacept retention in biologic-naïve patients.
Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.

Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.
Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI
Multivariable model of abatacept retention by RF and anti-CCP status in biologic-naïve patients with or without radiographic erosion at baseline. Multivariable.

Multivariable model of abatacept retention by RF and anti-CCP status in biologic-naïve patients with or without radiographic erosion at baseline. Multivariable.
Flow chart of the steps in the EMEUNET Peer Review Mentoring Program.

Flow chart of the steps in the EMEUNET Peer Review Mentoring Program.
Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.

Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.
Changes in evaluation indicators from baseline to 12 weeks per visit.

Changes in evaluation indicators from baseline to 12 weeks per visit.
Figure 1 Patient selection flow chart

Figure 1 Patient selection flow chart
Subgroup analyses of association of gout with incident AF by key demographic characteristics, race and gender. Subgroup analyses of association of gout.

Subgroup analyses of association of gout with incident AF by key demographic characteristics, race and gender. Subgroup analyses of association of gout.
Time to discontinuation of TNF-inhibitors (TNF-i) and non-TNF-inhibitors (non-TNFi), non-adjusted (non-adj) and adjusted (adj) for propensity score survival.

Time to discontinuation of TNF-inhibitors (TNF-i) and non-TNF-inhibitors (non-TNFi), non-adjusted (non-adj) and adjusted (adj) for propensity score survival.
Percentage of patients achieving EULAR response

Percentage of patients achieving EULAR response
Association of disease parameters at the time of methotrexate reinitiation during the OLE based on propensity score matching. Association of disease parameters.

Association of disease parameters at the time of methotrexate reinitiation during the OLE based on propensity score matching. Association of disease parameters.
Flow diagram of the literature search process, including exclusions and reasons for exclusions. *Population of pregnant women (n=2), asymptomatic antiphospholipid.

Flow diagram of the literature search process, including exclusions and reasons for exclusions. *Population of pregnant women (n=2), asymptomatic antiphospholipid.
Subgroup analysis of the 17 trials comparing haloperidol and placebo in schizophrenia (outcome: response rate). Subgroup analysis of the 17 trials comparing.

Subgroup analysis of the 17 trials comparing haloperidol and placebo in schizophrenia (outcome: response rate). Subgroup analysis of the 17 trials comparing.
Cells and mediators of the immune-inflammatory ‘cascade’ leading to overt clinical rheumatoid arthritis are described. Cells and mediators of the immune-inflammatory.

Cells and mediators of the immune-inflammatory ‘cascade’ leading to overt clinical rheumatoid arthritis are described. Cells and mediators of the immune-inflammatory.
The patient profiles presented to rheumatologists in the discrete choice experiment (DCE). aCCP, anti-cyclic citrullinated peptide; DAS28, 28-joint Disease.

The patient profiles presented to rheumatologists in the discrete choice experiment (DCE). aCCP, anti-cyclic citrullinated peptide; DAS28, 28-joint Disease.
Frequency of patients in flare at each time point over 3 months

Frequency of patients in flare at each time point over 3 months
Schematic presentation of enrichment through linkages of clinical Rheumatology register data to other national data sources within each of the five Nordic.

Schematic presentation of enrichment through linkages of clinical Rheumatology register data to other national data sources within each of the five Nordic.
Resolution of tophi after exposure to pegloticase.

Resolution of tophi after exposure to pegloticase.

Similar presentations

Ads by Google